Department of Clinical Pharmacy, Pharmacy Sciences, Al-Sadr Medical City, Al-Najaf Health Directorate, Al Najaf Al-Ashraf, Iraq.
Faculty of Pharmacy, University of Kufa, Iraq.
Med Arch. 2021 Oct;75(5):351-355. doi: 10.5455/medarh.2021.75.351-355.
Venous thromboembolism (VTE) is one of the most common cardiovascular disorders in the United States and is manifested as deep vein thrombosis (DVT) and pulmonary embolism (PE) which represented as the most important cause of death in pregnant women after cesarean section. Venous thromboembolism (VTE) is representing the second direct cause of death which is accounting for 13.8% of all mother's death in the world. The most common risk factor of venous thromboembolism (VTE) is cesarean section.
The study aims to study the current practice of post-cesarean thromboprophylaxis in dosing calculation and duration of therapy.
Between September 2020 and January 2021, an observational- interventional prospective pre and post-study, was conducted in all hospital of Najaf in the City center and the suburbs that contain gynecology and obstetric ward to assess the current practice of post-cesarean thromboprophylaxis and to evaluate the impact of pharmacist intervention program to improve guideline adherence then after intervention. Another 102 patients were enrolled to analyze the change thromboprophylaxis according to the guideline.
From patient data, the rate of adherence to guidelines raised significantly among the post-intervention patients' group by thromboprophylaxis dose according to body weight was increase significantly (p<0.001) from 56.9% in the observation phase to 83.3% after intervention and about the duration of thromboprophylaxis is significantly (p<0.001) from 18.6% in the observation phase to 52.0% after the intervention.
This study showed that the clinical pharmacist's multifaceted intervention has resulted in encouraging guideline implementations as reflected by improving the proper use of thromboprophylaxis the duration anddosing calculations according to body weight.
静脉血栓栓塞症(VTE)是美国最常见的心血管疾病之一,表现为深静脉血栓形成(DVT)和肺栓塞(PE),这是剖宫产后孕妇死亡的最重要原因。静脉血栓栓塞症(VTE)是第二大直接死因,占全球所有产妇死亡的 13.8%。静脉血栓栓塞症(VTE)最常见的危险因素是剖宫产。
本研究旨在研究剖宫产术后血栓预防的剂量计算和治疗持续时间的现状。
2020 年 9 月至 2021 年 1 月,在纳杰夫市中心和郊区的所有医院进行了一项观察性干预性前瞻性前后研究,评估了剖宫产术后血栓预防的现状,并评估了药师干预方案对提高指南依从性的影响,然后进行了干预。另外招募了 102 名患者,根据指南分析了血栓预防的变化。
从患者数据来看,干预后患者组的指南依从率显著提高,根据体重计算的血栓预防剂量显著增加(p<0.001),从观察阶段的 56.9%增加到干预后的 83.3%,而血栓预防的持续时间也显著增加(p<0.001),从观察阶段的 18.6%增加到干预后的 52.0%。
本研究表明,临床药师的多方面干预措施促使指南的实施得到了令人鼓舞的改进,体现在根据体重正确使用血栓预防药物的持续时间和剂量计算方面。